14 results about "Patient survival" patented technology

The present invention relates to a biomarker for predicting immunotherapeutic responsiveness based on spatial transcriptome analysis and uses thereof and, in particular, to: a marker composition for predicting the responsiveness of cancer patients to immunotherapy; a composition for predicting the responsiveness of cancer patients to immunotherapy; a kit for predicting the responsiveness of cancer patients to immunotherapy, comprising the composition; a method for providing information for predicting the responsiveness of cancer patients to immunotherapy; and a method for providing information for predicting the survival prognosis of cancer patients. The biomarker for predicting immunotherapeutic responsiveness, according to the present invention, was discovered by applying spatial transcriptome technology and analyzing cell group-specific gene expression values according to location information of cells in tissue sections, and can more precisely and accurately predict the responsiveness of cancer patients to immunotherapy and the survival prognosis of patients, thus enabling suitable treatments for patient groups, which may result in improved therapeutic effects and a reduction in pain and costs for patients.

The application discloses a cancer survival prediction method and device based on whole-slice pathological images, and relates to the technical field of medical artificial intelligence and digital pathological image analysis. The method comprises the following steps: acquiring whole-slice pathological images and patient survival information, and performing pretreatment; performing cell detection on the whole-slice pathological images to obtain cell structure data; dividing the whole-slice pathological images into a plurality of image regions, and determining regions of interest; screening the cell structure data in each region of interest to construct a cell subset; sorting the cell structure data according to the distribution relationship of cells in space to construct a cell structure sequence; constructing a cell structure modeling model, performing feature modeling on the cell structure sequence, and obtaining tissue structure features capable of representing the microstructure of tumor tissues; and inputting the tissue structure features into a survival prediction model to predict the survival risk of the patient. The application can improve the accuracy and stability of cancer survival prediction.

The application belongs to the technical field of tumor immunotherapy, and particularly relates to a composition for enhancing tumor immunogenicity and application thereof. The composition for enhancing tumor immunogenicity comprises, in terms of mass fraction, 10-15 parts of radix stephaniae tetrandrae, 10-20 parts of radix astragali, 3-9 parts of glycyrrhiza uralensis, and 3-12 parts of atractylodes macrocephala. The composition for enhancing tumor immunogenicity provided by the application is a natural traditional Chinese medicine prescription, has good biocompatibility, low toxicity and side effects, and is suitable for long-term treatment. The composition enhances immunogenicity by up-regulating MHC-I expression of tumor cells, activates CD8 + T cell-mediated anti-tumor effect, realizes autologous immunotherapy, and can avoid related side effects of exogenous immunotherapy. The composition can also be used in combination with a PD-1 blocker to synergistically improve anti-tumor efficacy and prolong patient survival.

This invention provides an irinotecan-conjugated polypeptide compound, its preparation method, and its application, belonging to the field of biomedical technology. Irinotecan (Dxd) is the active pharmaceutical ingredient. Irinotecan belongs to the topoisomerase I inhibitor class—camptothecin derivatives—and is a semi-synthetic small molecule chemotherapeutic drug capable of directly killing cancer cells in the active division phase and inhibiting tumor growth. TYLCTACDYTHH is a highly effective PDPN-targeting peptide that can effectively target the PDPN site in human glioblastoma. In vitro and in vivo experimental results show that the conjugated compound of this invention can significantly inhibit the proliferation of primary glioblastoma cells and effectively inhibit the growth of intracranial orthotopic xenografts in NOD-SCID mice, demonstrating good anti-tumor activity. This compound shows promise for targeted therapy of glioblastoma and has the potential to prolong patient survival.

This invention belongs to the field of biomedical technology and provides the application of 16'-DEC in the preparation of anti-hepatocellular carcinoma drugs. This bisindole alkaloid compound can inhibit the proliferation and migration of hepatocellular carcinoma cells and can produce a synergistic anti-tumor effect with lenvatinib, solving the problems of limited efficacy and insufficient patient survival benefit of existing targeted drugs in hepatocellular carcinoma treatment. Experiments have confirmed that 16'-DEC exerts its anti-tumor effect by directly inhibiting mTOR kinase activity. This compound can specifically bind to mTOR protein, significantly upregulate the expression of autophagy-related genes by blocking the mTOR signaling pathway, and induce autophagic cell death in tumor cells. In vitro and in vivo experiments have demonstrated that inhibiting autophagy can reverse the anti-cancer effect of 16'-DEC, indicating that its pharmacodynamic mechanism mainly depends on the activation of the autophagy pathway. This invention is applicable to the development of novel targeted therapies for hepatocellular carcinoma, especially specific inhibitors of the mTOR signaling pathway.

w The invention discloses a detection method for predicting efficacy and prognosis of immunotherapy for small cell lung cancer based on ATAD2 expression, and relates to the technical fields of molecular biology and cancer treatment. The method comprises the following steps: extracting a tumor tissue sample of a small cell lung cancer patient through surgical resection; Detecting the tumor tissue sample to obtain ATAD2 expression level, wherein the detection adopts an immunohistochemical staining method. According to the invention, the expression level of ATAD2 in tumor tissues of small cell lung cancer is quantitatively evaluated by immunohistochemical detection technology, and the molecular marker information is systematically correlated with the clinical and pathological characteristics of patients by combining Cox regression analysis and Logistic regression analysis, so that the comprehensive prediction of immunotherapy efficacy and patient survival time is realized.

The present application relates to the field of biotechnology, and in particular, discloses a marker for diagnosing sepsis and use thereof. The present application first discovers that serum METRNL can predict the survival of sepsis patients, and METRNL can be used as a marker for predicting the survival of sepsis patients. The AUC of METRNL combined with PCT for diagnosing sepsis can reach 1. Compared with the diagnosis effect of a single marker, the AUC value and specificity of METRNL combined with PCT are significantly improved, and sepsis patients can be completely distinguished, which is an ideal sepsis diagnostic index.

This invention discloses a bone repair scaffold system for tumor early warning and non-invasive treatment, comprising a bone repair scaffold, a microenvironment monitoring RFID module, a controlled drug release module, a signal reading system, and a cloud processor. The bone repair scaffold is shaped to fit the wound site and has a porous internal structure. The microenvironment monitoring RFID module is disposed on the internal and external surfaces of the bone repair scaffold. The controlled drug release module includes a microwave induction module and a drug storage unit. An external microwave excitation causes the microwave induction module to heat up, stimulating the thermoresponsive drug storage unit to release the drug. The signal reading system communicates with the microenvironment monitoring RFID module via radio frequency and is interconnected with the cloud processor via the internet. This invention can promote bone repair while rapidly monitoring tumor recurrence, alerting patients to seek medical attention early. Simultaneously, the drug release module enables non-invasive treatment, reducing patient suffering, improving quality of life, and prolonging survival.

This invention provides a liver-targeting glycoligand molecule modified with dual-antenna GalNAc and its drug delivery system. This liver-targeting glycoligand molecule and its drug delivery system, through ASGPR recognition, can maximize the concentration of therapeutic drugs in liver tumor parenchymal cells, thereby improving the targeting of drug distribution, increasing the therapeutic index, reducing systemic toxicity, and improving patient survival time and quality of life. The liver-targeting glycoligand molecule of this invention is synthesized using an enzymatic synthesis method, which involves fewer synthesis steps, mild enzymatic reaction conditions, high regioselectivity, high reaction efficiency, is environmentally friendly, and has low production costs, making it highly promising for industrialization.

The application belongs to the technical field of medical treatment and discloses a cancer prognosis marker combination and application thereof, which comprises the following markers: CD68, PD-L1, PAN-CK, HLA-DR, CD45, CD11c and Collagen I. The cancer prognosis evaluation model trained by using the 7-marker combination exhibits superior prognosis accuracy compared to a model relying on high-dimensional multi-omics data. The application proposes a multiple immunohistochemistry (mIHC) cancer prognosis evaluation detection product based on the above-mentioned cancer prognosis marker combination. Satisfactory prognosis results are achieved by using only two five-marker combinations. The method exhibits high accuracy in predicting the survival of gastric cancer patients, so that it becomes a low-cost, high-benefit and scalable solution for other cancers.

The application discloses an aviation medical rescue task simulation system and method, which comprises a task assumption module, a simulation module and a scheme evaluation module.The task assumption module comprises an assumption database module and a task assumption deployment interface.The assumption database module is used for providing a medical rescue aircraft equipment and medical equipment database and a patient survival model information database, and the task assumption deployment interface is used for editing the task assumption.The simulation module is used for simulating aviation medical field first-aid tasks, short-distance transfer tasks and long-distance transfer tasks.The scheme evaluation module is used for collecting and processing data after simulation deduction, and outputting multi-aspect task evaluation including single-machine indexes, task indexes and comprehensive performance indexes.Through integrating the three modules of task assumption, simulation deduction and scheme evaluation, the aviation medical rescue task simulation evaluation is realized, which provides a reference for improving rescue efficiency and accuracy, optimizing resource allocation and making scientific decisions.

A method of predicting overall survivability of a patient by a prediction system based on machine learning includes receiving, by the prediction system, first modality data and second modality data corresponding to the patient; generating, by the prediction system, a first intermediate feature vector and a second intermediate feature vector based on the first and second modality data; determining, by the prediction system, a first attention score and a second attention score based on the first and second intermediate feature vectors; generating, by the prediction system, an aggregate feature vector based on the first and second intermediate feature vectors and the first and second attention scores; and generating, by the prediction system, a survivability prediction corresponding to the patient based on the aggregate feature vector.

This invention discloses a siRNA or shRNA construct for inhibiting RSRC1 expression and its application, relating to the field of biomedical technology. It includes a specific nucleotide sequence targeting human RSRC1 gene mRNA; this specific nucleotide sequence can specifically bind to the coding region (CDS) or 3' untranslated region (3'UTR) of the RSRC1 gene, mediating the degradation or translational repression of RSRC1 mRNA, thereby reducing the intracellular expression level of RSRC1 protein; the construct is configured to block the direct interaction between RSRC1 protein and DVL2 protein, thereby inhibiting the activation of downstream Wnt / β-catenin signaling pathways and AKT / mTOR signaling pathways. This invention, while inducing tumor cell apoptosis, inhibiting colony formation, and reducing metastatic nodules in vivo, avoids the limitations of single-target silencing in completely blocking multi-pathway cross-talk, ultimately achieving a synergistic therapeutic effect of significantly reducing chemotherapy resistance, inhibiting metastasis of advanced ovarian cancer, and prolonging patient survival.

The application belongs to the field of biological medicine, and relates to a combination of a DR5 agonist and an immune checkpoint inhibitor for preparing a drug for treating tumors. The application provides application of a death receptor 5 agonist in preparation of an anti-tumor drug in combination with one or more of a PD-1 inhibitor, a PD-L1 inhibitor, a NKG2A inhibitor and a chemotherapeutic drug. It is found that the DR5 agonistic antibody can further increase the single drug efficacy of the immune checkpoint inhibitor. On this basis, the DR5 agonistic antibody and the immune checkpoint inhibitor can also be combined with chemotherapy to further improve the effect of immunotherapy. The application can further promote the development of immunotherapy in the field of tumor treatment, optimize the tumor treatment pattern, and is expected to be applied in the clinic to improve the tumor treatment effect and the survival rate of patients.